Drugs & Targets Linvoseltamab BLA accepted for Priority Review for R/R multiple myeloma February 23, 2024Vol.50 No.08
Drugs & Targets FDA OCE annual report lists 83 cancer therapeutic approvals in 2023 February 23, 2024Vol.50 No.08
Drugs & Targets FDA approves Onivyde for first-line treatment of metastatic pancreatic adenocarcinoma February 16, 2024Vol.50 No.07
Drugs & Targets FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors February 16, 2024Vol.50 No.07
Regulatory News FDA tells sponsors of CAR T-cell therapies to add boxed warning about secondary T-cell malignancies February 02, 2024Vol.50 No.05By Alexandria Carolan
Guest Editorial Reflecting on Janet Woodcock’s retirement from FDA January 26, 2024Vol.50 No.04By Ellen V. Sigal
Drugs & Targets FDA approves Balversa for locally advanced or metastatic urothelial carcinoma January 26, 2024Vol.50 No.04
In Brief Kelly Norsworthy named acting associate director for research mentorship in FDA’s Oncology Center of Excellence January 19, 2024Vol.50 No.03
